COMPANY

Acomhal Research

HQ: Roanoke, VA source · acomhal.com ↗ · Southeast

We are developing a targeted adjunct therapy aimed at tackling chemo-resistant cells in aggressive cancers, including glioblastoma, breast, colon, lung, and pancreatic cancers. From company website Source · Oct 12, 2026

Location: Roanoke, VA · source · Apr 20, 2021

Profile checked Oct 10, 2026

3NIH grants

NIH awards 3

Annual award amounts. Total $1.0M.

Sep 17, 2026 NIH award 1R41CA306619-01A1 FY2026: $400,000 awarded for that fiscal year; activity R41 (STTR); PI LAMOUILLE, SAMY; recipient as written: ACOMHAL RESEARCH, INC., ROANOKE, VA. Alphavirus vector-mediated expression of source ↗
Jun 25, 2020 NIH award 1R41CA250874-01 FY2020: $399,878 awarded for that fiscal year; activity R41 (STTR); PI LAMOUILLE, SAMY; recipient as written: ACOMHAL RESEARCH, INC., ROANOKE, VA. Inhibition of breast cancer cell metastases source ↗
Aug 24, 2017 NIH award 1R41CA217503-01 FY2017: $224,999 awarded for that fiscal year; activity R41 (STTR); PI LAMOUILLE, SAMY; recipient as written: ACOMHAL RESEARCH, INC., ROANOKE, VA. Therapeutic disruption of Connexin43-mediat source ↗

Funding and NIH signals

NIH award NIH awarded $400K (STTR Phase I 1R41CA306619-01A1, new, notice Sep 17, 2026). NIH RePORTER 1R41CA306619-01A1 (Sep 17, 2026)
Evidence (1 event)
- Sep 17, 2026 · NIH RePORTER 1R41CA306619-01A1
  Organization: ACOMHAL RESEARCH, INC.; City/State: ROANOKE, VA; Project number: 1R41CA306619-01A1; Activity code: R41; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 400000; Administering IC: National Cancer Institute; Project title: Alphavirus vector-mediated expression of a connexin43 mimetic peptide in glioblastoma therapy; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals